European Heart Journal vs Lancet Oncology: Which Journal Should You Choose?

EHJ asks whether the paper matters to cardiologists. Lancet Oncology asks whether the paper changes oncology practice at a global level.

That difference should drive the submission choice.

If the manuscript depends on ESC relevance, cardiovascular surveillance, imaging, heart-failure logic, or cardiac risk interpretation, EHJ usually becomes the better home. If the manuscript depends on oncology trial logic, treatment standards, global clinical consequence, or practice change for oncologists, Lancet Oncology usually becomes the better home.

EHJ wins when the cardio-oncology manuscript is fundamentally a cardiovascular paper.

That usually means:

• cardiotoxicity surveillance and monitoring
• cardiovascular outcomes after cancer therapy
• imaging or biomarker work that cardiologists must act on
• registries and outcome analyses with a cardiovascular practice consequence

EHJ's editorial guidance are clear that the journal wants broad cardiology consequence and a field-facing cardiovascular story.

Lancet Oncology wins when the manuscript is fundamentally an oncology paper.

That includes:

• clinical trials where the main message is cancer treatment strategy
• oncology practice change with important but secondary cardiovascular findings
• survivorship or toxicity work that mainly changes oncologist behavior
• globally relevant oncology evidence with strong clinical consequences

Lancet Oncology's editorial guidance are explicit that the journal wants papers that change what oncologists do, not just interesting mechanism or local observation.

EHJ's cover letter and structure are cardiology-first

EHJ submission's editorial guidance emphasizes ESC guidelines, European cardiovascular practice, structured abstracts, graphical abstracts, and cardiology-facing significance. That means the paper belongs there only if the cardiovascular consequence is the actual lead.

Lancet Oncology has a stronger global-practice filter

The Lancet Oncology source set emphasizes Research in Context, in-house statistical review, and practice-changing clinical relevance. It isn't enough to be oncology-adjacent. The study has to matter to how oncologists practice.

EHJ is more comfortable with cardiovascular-native framing

Cardiology language, risk logic, and imaging or outcomes nuance are expected there.

Lancet Oncology is more comfortable with oncology-native framing

If the manuscript is still fundamentally about treatment, cancer outcomes, or global oncology practice, that's a strength there, not a weakness.

• the paper is fundamentally cardiovascular
• cardiologists are the main audience
• cardiovascular surveillance, outcomes, or ESC relevance are central
• the manuscript becomes stronger when written for cardiology readers

That's the EHJ lane.

• the paper is fundamentally oncology-led
• oncologists are the main audience
• treatment strategy or global oncology consequence is central
• the manuscript becomes stronger when written for oncology readers

That's the Lancet Oncology lane.

This isn't a simple prestige cascade.

A paper rejected by EHJ does not automatically become a Lancet Oncology paper, and vice versa.

The cascade only works when the first journal saw the manuscript as belonging more naturally to the other specialty.

That can happen when:

• the paper sits at the cardio-oncology boundary
• the methods are strong
• the question matters to both fields
• the first journal judged that the primary readership was actually the other specialty

It doesn't work when the study is simply too narrow or too weak for either field-leading journal.

EHJ punishes papers that are too oncology-defined

If the cardiovascular consequence feels secondary to the cancer story, EHJ gets harder quickly.

Lancet Oncology punishes papers that are too cardiology-defined

If the main action belongs to cardiologists and the oncology context is mostly background, Lancet Oncology gets harder quickly.

EHJ punishes narrow cardiovascular consequence

The journal still wants field-wide cardiology relevance, not only competent cardio-oncology analysis.

Lancet Oncology punishes immature or non-practice-changing oncology evidence

The journal's editorial guidelines are blunt that early, weakly validated, or non-clinical oncology stories struggle badly there.

Cardiotoxicity monitoring and cardiovascular management

These are usually cleaner EHJ papers when the goal is to change cardiovascular practice.

Cancer trial papers with important cardiac outcomes

These are often cleaner Lancet Oncology papers when the main consequence is still oncology treatment strategy.

Survivorship and long-term risk work

This category can go either way. If the primary field that needs to act is cardiology, EHJ usually wins. If the primary field is oncology, Lancet Oncology usually wins.

Global oncology analyses with cardiovascular endpoints

The key question is whether the paper is really about cancer practice or cardiac management. That usually tells you the right target.

A strong EHJ first page makes the cardiovascular consequence obvious immediately. The reader should understand why cardiologists need this paper now.

A strong Lancet Oncology first page makes the oncology consequence obvious immediately. The reader should understand why oncologists need this paper now.

If you need both first pages at once, the paper may still be undecided about its true audience.

Ask which sentence fits the manuscript better:

• "this changes what cardiologists should do or think" points toward European Heart Journal
• "this changes what oncologists should do or think worldwide" points toward Lancet Oncology

That sentence is often the most honest submission test.

At the cardio-oncology boundary, the wrong readership can flatten a very strong paper. A study that's excellent for cardiologists can look too secondary to oncologists. A study that's excellent for oncologists can look only indirectly actionable for cardiologists.

That's why audience clarity matters more than brand reflexes in this comparison.

Send to European Heart Journal first if:

1. the paper is fundamentally cardiovascular
2. cardiologists are the readers who most need it
3. ESC-facing relevance or cardiovascular management is central
4. the paper gets stronger when written for cardiology

Send to Lancet Oncology first if:

1. the paper is fundamentally oncology-led
2. oncologists are the readers who most need it
3. treatment strategy or global oncology practice is central
4. the paper gets stronger when written for oncology

That is also why the safer strategy is usually to write the cover letter for the audience that will understand the claim fastest. If that audience is narrower, you usually shouldn't hide from that. You should submit to the journal that can judge the paper on the right terms the first time.